Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis

被引:7
|
作者
Jiang, Dandan [1 ]
Ma, Peizhi [1 ]
机构
[1] Peoples Hosp Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Pharm, Zhengzhou, Henan, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
中国国家自然科学基金;
关键词
gastric cancer; HDAC6; EMT; canagliflozin; enzyme inhibition; TARGET;
D O I
10.3389/fonc.2022.1057455
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastric cancer is a common gastrointestinal cancer. Survival outcome for patients with the recurrence or metastasis remains poor due to the lack of effective targeting drugs. The mechanisms of non-histone acetylation modifications are key epigenetic regulations that participate in various biological processes. HDAC6 is mostly located in the cytoplasm to deacetylate non-histone substrates, which has been identified as a critical promoter of many oncogenic pathways in cancers, including gastric cancer. Nevertheless, its inhibitor has not been applied in gastric cancer clinically. In this study, we identified canagliflozin as an active HDAC6-targeted inhibitor from FDA-approved Drug Library by enzymatic assay. The strong affinity of the compounds with HDAC6 was further verified by surface plasmon resonance (SPR) and cellular thermal shift assay (CETSA). In addition, molecular docking showed that canagliflozin could bind to the active pocket of HDAC6 and form interactions with key residues. Further experiments revealed that canagliflozin could effectively inhibit the migration and epithelial-mesenchymal-transition (EMT) of gastric cancer cells in vitro and in vivo. These results reveal a novel finding that canagliflozin has the potential to be an effective agent in inhibiting gastric cancer metastasis.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] PET imaging assist investigation of HDAC6 expression change in MDD and evaluating antidepressant efficacy of a newly developed HDAC6 inhibitor
    Zhong, Xiao
    Wu, Xiaoai
    Zhou, Yanting
    Wu, Rui
    Yang, Jingyi
    Yin, Honghai
    Meng, Hui
    Xie, Weiyao
    Liu, Gang
    Wang, Changning
    Bai, Ping
    Zhang, Wei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 280
  • [32] High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma
    Liu, Jia-Rong
    Yu, Chao-Wu
    Hung, Pei-Yun
    Hsin, Ling-Wei
    Chern, Ji-Wang
    BIOCHEMICAL PHARMACOLOGY, 2019, 163 : 458 - 471
  • [33] HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
    Hideshima, Teru
    Mazitschek, Ralph
    Qi, Jun
    Mimura, Naoya
    Tseng, Jen-Chieh
    Kung, Andrew L.
    Bradner, James E.
    Anderson, Kenneth C.
    ONCOTARGET, 2017, 8 (46) : 80109 - 80123
  • [34] miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6
    Wang, Xiao-chun
    Ma, Ying
    Meng, Pei-song
    Han, Jia-long
    Yu, Hai-yan
    Bi, Liang-jia
    ORAL ONCOLOGY, 2015, 51 (07) : 674 - 682
  • [36] In vivo evaluation of Ames negative HDAC6 inhibitor in melanoma model
    Hadley, Melissa
    Shen, Sida
    Banik, Debarati
    Kim, Jennifer
    Nair, Jayakumar
    Knox, Tessa
    Gallub, Vincent
    Kirkland, Shannon
    Chiappinelli, Katherine B.
    Sotomayor, Eduardo
    Kozikowski, Alan
    Villagra, Alejandro
    CANCER RESEARCH, 2017, 77
  • [37] Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma
    Auzmendi-Iriarte, Jaione
    Saenz-Antonanzas, Ander
    Mikelez-Alonso, Idoia
    Carrasco-Garcia, Estefania
    Tellaetxe-Abete, Maitena
    Lawrie, Charles H.
    Sampron, Nicolas
    Cortajarena, Aitziber L.
    Matheu, Ander
    CELL DEATH & DISEASE, 2020, 11 (06)
  • [38] Growth suppression of glioma cells using HDAC6 inhibitor, tubacin
    Yin, Changjiang
    Li, Pibao
    OPEN MEDICINE, 2018, 13 (01): : 221 - 226
  • [39] Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma
    Jaione Auzmendi-Iriarte
    Ander Saenz-Antoñanzas
    Idoia Mikelez-Alonso
    Estefania Carrasco-Garcia
    Maitena Tellaetxe-Abete
    Charles H. Lawrie
    Nicolás Sampron
    Aitziber L. Cortajarena
    Ander Matheu
    Cell Death & Disease, 11
  • [40] The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
    Sun, Xiaoyang
    Xie, Yu
    Sun, Xiaoshen
    Yao, Yao
    Li, Hujun
    Li, Zhenyu
    Yao, Ruosi
    Xu, Kailin
    BIOSCIENCE REPORTS, 2019, 39